Project Grant R61CA302538
Award Date 8/11/26
Completion Date 7/31/29
Dollars Obligated $239K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Newark, NJ 07107, USA
Similar Awards
- The National Cancer Institute awarded Rutgers The State University of New Jersey, doing business as RBHS-School of Nursing, $599,978 under the Cancer Cause and Prevention Research program (CFDA 93.393) on July 1, 2026. The award funds a five-year prospective cohort study examining the relationship between perceived social obligations and clinical and patient-reported outcomes in 315 patients with advanced, poor-prognosis cancer. The research tests the hypothesis that higher patient-reported...
- The National Cancer Institute awarded Rutgers The State University of New Jersey $651,548 on July 27, 2026, under the Cancer Treatment Research program (CFDA 93.395) to expand the repertoire of T cell receptor (TCR)-based therapies for human papillomavirus 16 (HPV16)-associated cancers beyond HLA-A*02:01 restriction. The recipient will systematically identify and validate TCRs restricted by prevalent HLA class I alleles including HLA-C07:01, C04:01, C07:02, A01:01, A03:01, and B07:02. Work...
- The National Cancer Institute awarded Rutgers The State University of New Jersey, doing business as RBHS-School of Nursing, $170,930 under Project Grant R03CA308463 on April 1, 2026, to support research into the longitudinal dynamics of blood microbiome and circulating tumor cells in metastatic breast cancer. The research applies a novel reduced metagenomic sequencing technique to analyze longitudinal plasma samples from women with metastatic triple-negative breast cancer (MTNBC), using liquid...
- The National Cancer Institute awarded Rutgers The State University of New Jersey, doing business as RBHS-School of Nursing, $516,808 under the Cancer Treatment Research program (CFDA 93.395) on June 1, 2026, to elucidate the mechanism of targeting methionine synthase (MTR) to enhance anti-tumor immunity in KRAS-driven lung cancer. The recipient will conduct research to understand how MTR targeting enhances immune responses in KRAS-driven non-small cell lung cancer (NSCLC), which exhibits...
- The National Cancer Institute awarded Rutgers The State University of New Jersey $672,960 on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate the implications of EP300 deficiency in adult T-cell leukemia/lymphoma (ATLL). The research addresses mechanisms underlying chemo-refractory ATLL in North American patients, who exhibit overall survival of only 6.9 months. The project leverages a unique collection of EP300-mutant ATLL cells and an EP300-specific PROTAC...
- The National Cancer Institute awarded Rutgers The State University of New Jersey, doing business as RBHS-School of Nursing, $303,431 on August 13, 2026, under the Cancer Research Manpower program (CFDA 93.398) to implement breast cancer early detection measures in primary healthcare facilities in Botswana. The award funds a five-year implementation research project guided by the Integrative Systems Praxis for Implementation Research (INSPIRE) methodology. The project will conduct key informant...
- The National Cancer Institute awarded a cooperative agreement to Rutgers The State University of New Jersey for $975,000 on March 21, 2026, under the Cancer Treatment Research program (CFDA 93.395). The award funds clinical trial support infrastructure and operations for the Rutgers Cancer Institute and RWJBarnabas Health System across multiple hospital sites within the health system. The award supports a centralized research administration model through the Office of Human Research Services,...
- The National Cancer Institute awarded New York University $703,227 on June 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop an ultra-rapid droplet digital PCR method for real-time molecular profiling of cancer-driving mutations during surgical resection. The funded work aims to engineer a microfluidic device that automates ultra-rapid DNA extraction and PCR thermal cycling to profile tissue samples in minutes rather than hours, enabling surgeons to...
- The National Cancer Institute awarded Rutgers The State University of New Jersey, School of Nursing, $723,569 under the Cancer Cause and Prevention Research program (CFDA 93.393) on September 1, 2026, to conduct a prospective epidemiologic study examining associations between the human gut microbiome and postmenopausal breast cancer risk. The research leverages the Nurses' Health Study II cohort, which includes over 18,000 women with pre-diagnostic stool samples and repeated assessments of...
- The National Cancer Institute awarded Rutgers The State University of New Jersey $542,316 on May 7, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate the mechanism and therapeutic potential of parkin in colorectal cancer. The funded research examines how the E3 ubiquitin ligase parkin suppresses colorectal cancer and how parkin deficiency drives metabolic reprogramming to promote disease progression. The project employs unbiased screening approaches including...